 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Celldex Therapeutics
CLDX
Conference or Release date: November 6, 2024 press release only
Celldex Jumps on CDX-0159 Data [June 15, 2020 @ Seeking Alpha]
Celldex Breast Cancer Phase 2 Study of glembatumumab vedotin fails [April 16, 2018]
Celldex Value Depends on Coming Data [February 8, 2018 @ Seeking Alpha]
Celldex Set to Bounce Back [April 15, 2015 @ Seeking Alpha]
| 2024 | |||
| Celldex Q1 2024 Press Release |
Celldex Q2 2024 Press Release |
Celldex Q2 2024 Press Release |
|
| May 6, 2024 | Aug. 8, 2024 | Nov. 6, 2024 | |
| 2023 | |||
| Celldex Q1 2023 Press Release |
Celldex Q2 2023 Press Release |
Celldex Q3 2023 Press Release |
Celldex Q4 2023 Press Release |
| May 4, 2023 | Aug. 8, 2023 | Nov. 2, 2023 | Feb. 26, 2024 |
| 2022 | |||
| Celldex Q1 2022 Press Release |
Celldex Q2 2022 Press Release |
Celldex Q3 2022 Press Release |
Celldex Q4 2022 Press Release |
| May 5, 2022 | Aug. 8, 2022 | Nov. 9, 2022 | Feb. 28, 2023 |
| 2021 | |||
| Celldex Q1 2021 Press Release |
Celldex Q2 2021 Press Release |
Celldex Q3 2021 Press Release |
Celldex Q4 2021 |
| May 6, 2021 | Aug. 5, 2021 | Nov. 9, 2021 | Feb. 28, 2022 |
| 2020 | |||
| Celldex Q1 2020 |
Celldex Q2 2020 |
Celldex Q3 2020 |
Celldex Q4 2020 |
| May 6, 2020 | Aug. 6, 2020 | Nov. 5, 2020 | March 29, 2021 |
| 2019 | |||
| Celldex Q1 2019 |
Celldex Q2 2019 |
Celldex Q3 2019 |
Celldex Q4 2019 |
| May 7, 2019 | August 7, 2019 | Nov. 11, 2019 | March 26, 2020 |
2018 |
|||
| Celldex Q4 2018 |
|||
May 10, 2018 |
August 8, 2018 |
Nov. 7, 2018 |
March 7, 2019 |
2017 |
|||
May 9, 2017 |
August 8, 2017 |
Nov. 11, 2017 |
March 7, 2018 |
2016 |
|||
05/05/2016 |
08/08/2016 |
11/07/2016 |
03/14/2017 |
2015 |
|||
Celldex Q2 analyst call not available |
|||
08/10/2015 |
11/05/2015 |
02/25/2016 |
|
Celldex Therapeutics (CLDX) is a biotechnology company developing therapies for cancers.
but did until 9/16/2020
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALLO |
| ALNY |
| AMAT |
| AMGN |
| APRE |
| ARWR |
| BIIB |
| BMY |
| CLDX |
| CLSN |
| FATE |
| GILD |
| GLYC |
| ILMN |
| INO |
| IONS |
| INCY |
| MCHP |
| MRNA |
| PLX |
| REGN |
| RNA |
| SANA |
| SAGE |
| SYRS |
| TSVT |
| VRTX |
| VSTM |
| WBA |
Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. This is investment journalism, not financial advice.
Copyright 2024 William P. Meyers